Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/7322
Title: CONTEMPORARY TREATMENT OF ALK POSITIVE NON SMALL CELL LUNG CANCER PATIENT WITH BRAIN METASTASES: OUR EXPERIENCE
Authors: Crvenova S 
Popova, Maja 
Keywords: CNS metastasis, ALK+ NSCLC patients, alectinib
Issue Date: 13-Jan-2020
Publisher: international journal of medical and biomedical studies
Journal: international journal of medical and biomedical studies
Abstract: Purpose: The aim of this study is to show alectinib efficacy and safety, with focus on alectinib intracranial efficacy. Case presentation: We report on a 46-year-old woman diagnosed as non small cell lung cancer harboring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. She has intracranial metastases and poor performance status of 3. We treated this patients with alectinib after whole brain irradiation and discontinuation of chemotherapy after two 2 cycles due to progressive brain and liver metastases. Good response was obtained with improving of her performance status without adverse events. Conclusions: We recommend alectinib as a treatment approach for ALK+ NSCLC patients, especially those with CNS metastases at the time of the diagnosis and poor PS.
URI: http://hdl.handle.net/20.500.12188/7322
Appears in Collections:Faculty of Medicine: Journal Articles

Files in This Item:
File Description SizeFormat 
835-Article Text-1244-1-10-20200131.pdfCONTEMPORARY TREATMENT OF ALK POSITIVE NON SMALL CELL LUNG CANCER PATIENT WITH BRAIN METASTASES: OUR EXPERIENCE1.02 MBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

14
checked on Jan 18, 2021

Download(s)

5
checked on Jan 18, 2021

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.